197 related articles for article (PubMed ID: 33162449)
1. [Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib].
Okahashi N; Uchihara M; Hoshino E
Rinsho Ketsueki; 2020; 61(10):1508-1510. PubMed ID: 33162449
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib Treatment through Nasogastric Tube in a Comatose Patient with Central Nervous System Localization of Mantle Cell Lymphoma.
Alsuliman T; Belghoul M; Choufi B
Case Rep Hematol; 2018; 2018():5761627. PubMed ID: 30186643
[TBL] [Abstract][Full Text] [Related]
3. [Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice].
Vorobyev VI; Gemdzhian EG; Fedorova LV; Mikhailova NB; Ilyasov RK; Kaleikina LP; Trubyakova OS; Kaplanov KD; Melnichenko EV; Martynova EV; Yakovleva EP; Li OY; Tarasenko EV; Chumakova EP; Bulieva NB; Nesterova ES; Margolin OV; Zherebtsova VA; Butaev LS; Ptushkin VV
Ter Arkh; 2021 Jul; 93(7):770-777. PubMed ID: 36286727
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.
Lauer EM; Waterhouse M; Braig M; Mutter J; Bleul S; Duque-Afonso J; Duyster J; Marks R; Reinacher PC; Prinz M; Illerhaus G; Finke J; Schorb E; Scherer F
Br J Haematol; 2020 Jul; 190(2):e110-e114. PubMed ID: 32452526
[No Abstract] [Full Text] [Related]
5. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.
Bernard S; Goldwirt L; Amorim S; Brice P; Brière J; de Kerviler E; Mourah S; Sauvageon H; Thieblemont C
Blood; 2015 Oct; 126(14):1695-8. PubMed ID: 26239089
[TBL] [Abstract][Full Text] [Related]
6. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.
Cheah CY; George A; Giné E; Chiappella A; Kluin-Nelemans HC; Jurczak W; Krawczyk K; Mocikova H; Klener P; Salek D; Walewski J; Szymczyk M; Smolej L; Auer RL; Ritchie DS; Arcaini L; Williams ME; Dreyling M; Seymour JF;
Ann Oncol; 2013 Aug; 24(8):2119-23. PubMed ID: 23616279
[TBL] [Abstract][Full Text] [Related]
7. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
Rusconi C; Cheah CY; Eyre TA; Tucker D; Klener P; Giné E; Crucitti L; Muzi C; Iadecola S; Infante G; Bernard S; Auer RL; Pagani C; Duglosz-Danecka M; Mocikova H; van Meerten T; Cencini E; Marin-Niebla A; Williams ME; Angelillo P; Nicoli P; Arcari A; Morello L; Mannina D; Vitagliano O; Sartori R; Chiappella A; Sciarra R; Stefani PM; Dreyling M; Seymour JF; Visco C
Blood; 2022 Oct; 140(17):1907-1916. PubMed ID: 35789260
[TBL] [Abstract][Full Text] [Related]
9. Durable remission with Bruton's tyrosine kinase inhibitor therapy in a patient with leptomeningeal disease secondary to relapsed mantle cell lymphoma.
Yohannan B; Sridhar A; Nguyen N; Rios A
BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35732356
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.
T Low J; B Peters K
CNS Oncol; 2020 Mar; 9(1):CNS51. PubMed ID: 32141313
[TBL] [Abstract][Full Text] [Related]
11. miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-κb signaling pathway in mantle cell lymphoma.
Yuan J; Zhang Q; Wu S; Yan S; Zhao R; Sun Y; Tian X; Zhou K
Exp Hematol; 2021 Nov; 103():52-59.e2. PubMed ID: 34474146
[TBL] [Abstract][Full Text] [Related]
12. IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.
Sancho JM; Marín-Niebla A; Fernández S; Capote FJ; Cañigral C; Grande C; Donato E; Zeberio I; Puerta JM; Rivas A; Pérez-Ceballos E; Vale A; Martín García-Sancho A; Salar A; González-Barca E; Teruel A; Pastoriza C; Conde-Royo D; Sánchez-García J; Barrenetxea C; Arranz R; Hernández-Rivas JÁ; Ramírez MJ; Jiménez A; Rubio-Azpeitia E
Int J Hematol; 2022 Sep; 116(3):381-392. PubMed ID: 35551632
[TBL] [Abstract][Full Text] [Related]
13. [Ibrutinib therapy for a blastoid variant mantle cell lymphoma patient with early extranodal relapse after autologous stem cell transplantation].
Nakamura K; Saburi M; Kondo Y; Soga Y; Itani K; Kohno K; Otsuka M; Nakayama T
Rinsho Ketsueki; 2019; 60(12):1663-1668. PubMed ID: 31902818
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.
Zhao X; Wang MY; Jiang H; Lwin T; Park PM; Gao J; Meads MB; Ren Y; Li T; Sun J; Fahmi NA; Singh S; Sehgal L; Wang X; Silva AS; Sotomayor EM; Shain KH; Cleveland JL; Wang M; Zhang W; Qi J; Shah BD; Tao J
Cell Rep; 2021 Mar; 34(11):108870. PubMed ID: 33730585
[TBL] [Abstract][Full Text] [Related]
15. Time-Resolved scRNA-Seq Tracks the Adaptation of a Sensitive MCL Cell Line to Ibrutinib Treatment.
Fuhr V; Vafadarnejad E; Dietrich O; Arampatzi P; Riedel A; Saliba AE; Rosenwald A; Rauert-Wunderlich H
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668876
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study.
Sharman J; Kabadi SM; Clark J; Andorsky D
Br J Haematol; 2021 Feb; 192(4):737-746. PubMed ID: 33095453
[TBL] [Abstract][Full Text] [Related]
17. The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma.
Tucker D; Morley N; MacLean P; Vandenberghe E; Booth S; Parisi L; Rule S
Br J Haematol; 2021 Mar; 192(6):1035-1038. PubMed ID: 32445482
[TBL] [Abstract][Full Text] [Related]
18. Mantle Cell Lymphoma with Central Nervous System Involvement Simulating Bilateral Subdural Hematomas.
González-Bonet LG; García-Boyero R; Gaona-Morales J
World Neurosurg; 2017 Mar; 99():808.e1-808.e2. PubMed ID: 28063897
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma.
Qualls D; Lam HY; Whiting K; Kumar A; Matasar M; Owens C; Nichols C; Espeleta JA; Qiu A; Subzwari S; Biggar E; Seshan V; Salles G; Younes A; Batlevi C
Blood Adv; 2022 Sep; 6(18):5262-5266. PubMed ID: 35171976
[No Abstract] [Full Text] [Related]
20. Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly.
Ruella M; Soubeyran P
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):432-436. PubMed ID: 27913512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]